• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Esophageal Cancer - Pipeline Review, H2 2012 Product Image

Esophageal Cancer - Pipeline Review, H2 2012

  • ID: 2366357
  • December 2012
  • 529 pages
  • Global Markets Direct

Esophageal Cancer – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Esophageal Cancer - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Esophageal Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Esophageal Cancer. Esophageal Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Esophageal Cancer.
- A review of the Esophageal Cancer products under development by companies and universities/research institutes READ MORE >

2
List of Tables 27
List of Figures 29
Introduction 30
REPORT COVERAGE 30
Esophageal Cancer Overview 31
Therapeutics Development 32
An Overview of Pipeline Products for Esophageal Cancer 32
Esophageal Cancer Therapeutics under Development by Companies 34
Esophageal Cancer Therapeutics under Investigation by Universities/Institutes 37
Late Stage Products 46
Comparative Analysis 46
Mid Clinical Stage Products 47
Comparative Analysis 47
Early Clinical Stage Products 48
Comparative Analysis 48
Discovery and Pre-Clinical Stage Products 49
Comparative Analysis 49
Esophageal Cancer Therapeutics – Products under Development by Companies 50
Esophageal Cancer Therapeutics – Products under Investigation by Universities/Institutes 52
Companies Involved in Esophageal Cancer Therapeutics Development 67
Bristol-Myers Squibb Company 67
F. Hoffmann-La Roche Ltd. 68
Shionogi & Co., Ltd. 69
Eli Lilly and Company 70
GlaxoSmithKline plc 71
Tekmira Pharmaceuticals Corp. 72
Bavarian Nordic A/S 73
Daiichi Sankyo Company, Ltd 74
YM BioSciences Inc. 75
Novartis AG 76
Aphios Corporation 77
Cell Therapeutics, Inc. 78
Neogenix Oncology Corporation 79
Transgene Biotek Ltd 80
Proteo, Inc. 81
Supratek Pharma Inc. 82
GANYMED Pharmaceuticals AG 83
Advantagene, Inc. 84
Ascenta Therapeutics, Inc. 85
Omeros Corporation 86
Kringle Pharma, Inc. 87
ImmunoFrontier, Inc. 88
Mebiopharm Co., Ltd. 89
Eurofarma 90
Biotech Pharmaceuticals Co., Ltd. 91
Esophageal Cancer – Therapeutics Assessment 92
Assessment by Monotherapy Products 92
Assessment by Combination Products 93
Assessment by Route of Administration 94
Assessment by Molecule Type 96
Drug Profiles 99
brivanib alaninate - Drug Profile 99
Product Description 99
Mechanism of Action 99
R&D Progress 99
paclitaxel poliglumex - Drug Profile 101
Product Description 101
Mechanism of Action 101
R&D Progress 101
Bryosomes - Drug Profile 103
Product Description 103
Mechanism of Action 103
R&D Progress 103
SP-1049C - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
Elafin - Drug Profile 106
Product Description 106
Mechanism of Action 106
R&D Progress 106
NK-4 Protein - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
iMAB-362 - Drug Profile 109
Product Description 109
Mechanism of Action 109
R&D Progress 109
Azacitidine + Oxaliplatin + Epirubicin + Capecitabine - Drug Profile 110
Product Description 110
Mechanism of Action 110
R&D Progress 110
Taxotere + 5-Fluorouracil + Briplatin - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
Cisplatin + Fluorouracil + Iressa + Radiation Therapy - Drug Profile 113
Product Description 113
Mechanism of Action 113
R&D Progress 114
Taxotere + Xeloda - Drug Profile 115
Product Description 115
Mechanism of Action 115
R&D Progress 115
Tarceva + Targretin - Drug Profile 117
Product Description 117
Mechanism of Action 117
R&D Progress 117
HPPH - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
Gefitinib + Radiation Therapy - Drug Profile 164
Product Description 164
Mechanism of Action 164
R&D Progress 164
TS-1 + Cisplatin + Radiation Therapy - Drug Profile 165
Product Description 165
Mechanism of Action 165
R&D Progress 165
Panitumumab + Cisplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile 167
Product Description 167
Mechanism of Action 167
R&D Progress 168
cetuximab - Drug Profile 169
Product Description 169
Mechanism of Action 169
R&D Progress 169
Tykerb + Capecitabine + Oxaliplatin - Drug Profile 170
Product Description 170
Mechanism of Action 170
R&D Progress 170
Sunitinib + FOLFIRI - Drug Profile 172
Product Description 172
Mechanism of Action 172
R&D Progress 173
Docetaxel + Cisplatin + 5-Fluorouracil - Drug Profile 217
Product Description 217
Mechanism of Action 217
R&D Progress 217
Oxaliplatin + Irinotecan - Drug Profile 219
Product Description 219
Mechanism of Action 219
R&D Progress 219
ZD6474 + Carboplatin + Paclitaxel + 5-Fluorouracil + Radiation Therapy - Drug Profile 220
Product Description 220
Mechanism of Action 220
R&D Progress 221
Cetuximab + Paclitaxel + Cisplatin + Radiotherapy - Drug Profile 222
Product Description 222
Mechanism of Action 222
R&D Progress 222
Irinotecan + Cisplatin - Drug Profile 224
Product Description 224
Mechanism of Action 224
R&D Progress 224
fluorouracil + leucovorin + irinotecan + nimotuzumab - Drug Profile 225
Product Description 225
Mechanism of Action 225
R&D Progress 226
Cisplatin + Capecitabine + Cetuximab + Radiation Therapy - Drug Profile 227
Product Description 227
Mechanism of Action 227
R&D Progress 227
Lobaplatin + 5-Fluorouracil + Leucovorin - Drug Profile 292
Product Description 292
Mechanism of Action 292
R&D Progress 292
Cetuximab + Oxaliplatin + Fluorouracil - Drug Profile 294
Product Description 294
Mechanism of Action 294
R&D Progress 295
Cisplatin + Fluorouracil + Paclitaxel + Radiation Therapy - Drug Profile 296
Product Description 296
Mechanism of Action 296
R&D Progress 296
IMF-001 - Drug Profile 298
Product Description 298
Mechanism of Action 298
R&D Progress 298
Docetaxel + Irinotecan + Radiation Therapy - Drug Profile 299
Product Description 299
Mechanism of Action 299
R&D Progress 299
Autologous Tumor Cell Vaccine + Iscomatrix + Celecoxib - Drug Profile 457
Product Description 457
Mechanism of Action 457
R&D Progress 457
Trastuzumab + Carboplatin + Paclitaxel - Drug Profile 458
Product Description 458
Mechanism of Action 458
R&D Progress 459
S-1 + Docetaxel + Radiation Therapy - Drug Profile 460
Product Description 460
Mechanism of Action 460
R&D Progress 461
Docetaxel + 5-Fluorouracil + Dexamethasone + Radiation Therapy - Drug Profile 462
Product Description 462
Mechanism of Action 462
R&D Progress 463
Oxaliplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile 464
Product Description 464
Mechanism of Action 464
R&D Progress 464
Docetaxel + Cisplatin - Drug Profile 466
Product Description 466
Mechanism of Action 466
R&D Progress 466
HLA-A-2402-restricted URLC10 Peptide Vaccine + CDCA1 + KOC1+ Montanide ISA 51 - Drug Profile 467
Product Description 467
Mechanism of Action 467
R&D Progress 467
Regorafenib - Drug Profile 492
Product Description 492
Mechanism of Action 492
R&D Progress 492
Vaccine For Esophageal Cancer - Drug Profile 493
Product Description 493
Mechanism of Action 493
R&D Progress 493
Esophageal Cancer Therapeutics – Drug Profile Updates 494
Esophageal Cancer Therapeutics – Discontinued Products 503
Esophageal Cancer Therapeutics - Dormant Products 506
Esophageal Cancer – Product Development Milestones 520
Featured News & Press Releases 520
Oct 25, 2012: Novelos Announces Enrollment Of First Patient In Solid Tumor Imaging Trial With I-124-CLR1404 At University Of Wisconsin Carbone Cancer Center 520
Oct 02, 2012: Merrimack Pharma Presents Phase I Study Results Of MM-111 At European Society for Medical Oncology 2012 521
Oct 01, 2012: MethylGene Presents Clinical Data On MGCD265 At European Society For Medical Oncology 2012 Congress 522
Jun 08, 2012: Cancer Research UK Launches Trial Of Experimental Drug Combination For Advanced Stomach And Oesophageal Cancer 523
Aug 09, 2011: Tekmira Announces Additional Clinical Trial Of TKM-PLK1 With US National Cancer Institute 524
Feb 23, 2011: CTI Announces Publication Of Phase II Study Results Of OPAXIO In American Journal Of Clinical Oncology 525
Jul 07, 2010: OPAXIO Phase II Study Results Confirm High Rate Of Complete Response With Low Rate Of Side Effects In Patients With Advanced Esophageal Cancer 526
Apr 22, 2010: Genentech Submits Supplemental Application To FDA For Herceptin In Advanced HER2-Positive Stomach Cancer 526
Feb 04, 2010: Proteo, Inc./Proteo Biotech AG: Orphan Drug Designation For Elafin In The Treatment Of Oesophagus Carcinoma 527
Nov 16, 2009: Proteo, Inc./Proteo Biotech AG: European Medicines Agency EMEA Recommends Orphan Drug Status For Elafin In The Treatment Of Esophagus Carcinoma 527
Appendix 528
Methodology 528
Coverage 528
Secondary Research 528
Primary Research 528
Expert Panel Validation 528
Contact Us 529
Disclaimer 529

List of Tables
Number of Products Under Development for Esophageal Cancer, H2 2012 32
Products under Development for Esophageal Cancer – Comparative Analysis, H2 2012 33
Number of Products under Development by Companies, H2 2012 35
Number of Products under Development by Companies, H2 2012 (Contd..1) 36
Number of Products under Investigation by Universities/Institutes, H2 2012 38
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 39
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 40
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 41
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 42
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 43
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 44
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 45
Comparative Analysis by Late Stage Development, H2 2012 46
Comparative Analysis by Mid Clinical Stage Development, H2 2012 47
Comparative Analysis by Early Clinical Stage Development, H2 2012 48
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 49
Products under Development by Companies, H2 2012 50
Products under Development by Companies, H2 2012 (Contd..1) 51
Products under Investigation by Universities/Institutes, H2 2012 52
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 53
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 54
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 55
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 56
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 57
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 58
Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 59
Products under Investigation by Universities/Institutes, H2 2012 (Contd..8) 60
Products under Investigation by Universities/Institutes, H2 2012 (Contd..9) 61
Products under Investigation by Universities/Institutes, H2 2012 (Contd..10) 62
Products under Investigation by Universities/Institutes, H2 2012 (Contd..11) 63
Products under Investigation by Universities/Institutes, H2 2012 (Contd..12) 64
Products under Investigation by Universities/Institutes, H2 2012 (Contd..13) 65
Products under Investigation by Universities/Institutes, H2 2012 (Contd..14) 66
Bristol-Myers Squibb Company, H2 2012 67
F. Hoffmann-La Roche Ltd., H2 2012 68
Shionogi & Co., Ltd., H2 2012 69
Eli Lilly and Company, H2 2012 70
GlaxoSmithKline plc, H2 2012 71
Tekmira Pharmaceuticals Corp., H2 2012 72
Bavarian Nordic A/S, H2 2012 73
Daiichi Sankyo Company, Ltd, H2 2012 74
YM BioSciences Inc., H2 2012 75
Novartis AG, H2 2012 76
Aphios Corporation, H2 2012 77
Cell Therapeutics, Inc., H2 2012 78
Neogenix Oncology Corporation, H2 2012 79
Transgene Biotek Ltd, H2 2012 80
Proteo, Inc., H2 2012 81
Supratek Pharma Inc., H2 2012 82
GANYMED Pharmaceuticals AG, H2 2012 83
Advantagene, Inc., H2 2012 84
Ascenta Therapeutics, Inc., H2 2012 85
Omeros Corporation, H2 2012 86
Kringle Pharma, Inc., H2 2012 87
ImmunoFrontier, Inc., H2 2012 88
Mebiopharm Co., Ltd., H2 2012 89
Eurofarma, H2 2012 90
Biotech Pharmaceuticals Co., Ltd., H2 2012 91
Assessment by Monotherapy Products, H2 2012 92
Assessment by Combination Products, H2 2012 93
Assessment by Stage and Route of Administration, H2 2012 95
Assessment by Stage and Molecule Type, H2 2012 98
Esophageal Cancer Therapeutics – Drug Profile Updates 494
Esophageal Cancer Therapeutics – Discontinued Products 503
Esophageal Cancer Therapeutics – Discontinued Products (Contd..1) 504
Esophageal Cancer Therapeutics – Discontinued Products (Contd..2) 505
Esophageal Cancer Therapeutics – Dormant Products 506
Esophageal Cancer Therapeutics – Dormant Products (Contd..1) 507
Esophageal Cancer Therapeutics – Dormant Products (Contd..2) 508
Esophageal Cancer Therapeutics – Dormant Products (Contd..3) 509
Esophageal Cancer Therapeutics – Dormant Products (Contd..4) 510
Esophageal Cancer Therapeutics – Dormant Products (Contd..5) 511
Esophageal Cancer Therapeutics – Dormant Products (Contd..6) 512
Esophageal Cancer Therapeutics – Dormant Products (Contd..7) 513
Esophageal Cancer Therapeutics – Dormant Products (Contd..8) 514
Esophageal Cancer Therapeutics – Dormant Products (Contd..9) 515
Esophageal Cancer Therapeutics – Dormant Products (Contd..10) 516
Esophageal Cancer Therapeutics – Dormant Products (Contd..11) 517
Esophageal Cancer Therapeutics – Dormant Products (Contd..12) 518
Esophageal Cancer Therapeutics – Dormant Products (Contd..13) 519

List of Figures
Number of Products under Development for Esophageal Cancer, H2 2012 32
Products under Development for Esophageal Cancer – Comparative Analysis, H2 2012 33
Products under Development by Companies, H2 2012 34
Products under Investigation by Universities/Institutes, H2 2012 37
Late Stage Products, H2 2012 46
Mid Clinical Stage Products, H2 2012 47
Early Clinical Stage Products, H2 2012 48
Discovery and Pre-Clinical Stage Products, H2 2012 49
Assessment by Monotherapy Products, H2 2012 92
Assessment by Combination Products, H2 2012 93
Assessment by Route of Administration, H2 2012 94
Assessment by Stage and Route of Administration, H2 2012 95
Assessment by Molecule Type, H2 2012 96
Assessment by Stage and Molecule Type, H2 2012 97

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos